Log In
BCIQ
Print this Print this
 

MT 400

  Manage Alerts
Collapse Summary General Information
Company Aralez Pharmaceuticals Inc.
DescriptionCombination of sumatriptan, a serotonin (5-HT1D) receptor agonist, and naproxen sodium, an NSAID
Molecular Target Serotonin (5-HT) receptor
Mechanism of ActionSerotonin (5-HT) receptor agonist; NSAID
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationMigraine
Indication DetailsTreat migraine
Regulatory Designation
PartnerDesitin Arzneimittel GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$3.0M

$0.5M

$2.5M


 Deals Details
Get a free BioCentury trial today